Market Access News | pharmaphorum

News

Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.

News

Prof Jonathan Benger will take over from Dr Sam Roberts as CEO of UK reimbursement authority NICE later this week, at a critical time for the agency.

News

Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.

News

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

News

Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.

News

GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.